PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2234-2243

  Carniti, Cristiana ^a   Perego, Carla ^b   Mondellini, Piera ^a   Alessandro Pierotti, Marco ^a,c   Bongarzone, Italia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 (4 METHYLPHENYL) 7 (TERT BUTYL)PYRAZOLO DEXTRO 3,4 PYRIMIDINE; CBL PROTEIN; ISOPROTEIN; LIGASE; ONCOPROTEIN; PROTEIN RET; PROTEOME; PYRAZOLOPYRIMIDINE DERIVATIVE; RECEPTOR; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFECT; EMBRYO; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; MALIGNANT TRANSFORMATION; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; ENZYME INHIBITORS; HUMANS; MICE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PYRAZOLES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; UBIQUITIN;

EID: 0037699063     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Takahashi, M. The GDNF/ ET signaling pathway and human diseases. Cytokine Growth Factor, 12: 361-373, 2001.
2. Manie, S., Santoro, M., Fusco, A., and Billaud, M, The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet., 17: 580-589, 2001.
3. Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., and Pachnis, V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature (Lond.), 367: 380-383, 1994.
4. Moore, M. W., Klein, R. D., Farinas, I., Sauer, H., Armanini, M., Phillips, H., Reichardt, L. F., Ryan, A. M., Carver-Moore, K., and Rosenthal, A. Renal and neuronal abnormalities in mice lacking GDNF. Nature (Lond.), 382: 76-79, 1996.
5. Pichel, J. G., Shen, L., Sheng, H. Z., Granholm, A. C., Drago, A., Grinberg, A., Lee, E. J., Huang, S. P., Saarma, M., Hoffer, B. J., Sariola, H., and Westphal, H. Defects in enteric innervation and kidney development in mice lacking GDNF, Nature (Lond.), 382: 73-76, 1996.
6. Sanchez, M. P., Silos-Santiago, I., Frisen, J., He, B., Lira, S. A., and Barbacid, M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature (Lond.), 382: 70-73, 1996.
7. Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, I. R., Moley, I. F., Goodfellow, P., and Wells, S. A., Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet., 2: 851-856, 1993.
8. Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C, Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papl, L., Ponder, M. A., Telenlus, H., Tunnacliffe, A., and Ponder, B. A. J. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (Lond.), 363: 458-460, 1993.
9. Hofstra, R. M., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., Ploos van Hamstel, H. K., Romeo, G., Lips, C. J. M., and Buys, C. H. C. M. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (Lond.), 367: 375-376, 1994.
10. Eng, C. RET proto-oncogene in the development of human cancer. J. Clin. Oncol., 17: 380-393, 1999.
11. Carlson, K. M., Dou, S., Chi, D., Scavarda, N. J., Toshima, K., Jackson, C. E., Wells, S. A., Jr., Goodfellow, P., and Donis-Keller, H. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. USA, 91: 1579-1583, 1994.
12. Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Porta, G., Fusco, A., and Vecchio, G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 60: 557-563, 1990.
13. Bongarzone, I., Monzini, N., Borrello, M. G., Carcano, C., Ferraresi, G., Arighi, E., Mondellini, P., Della Porta, G., and Pierotti, M. A. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RIa of cyclic AMP-dependent protein kinase A. Mol. Cell. Biol., 13: 358-366, 1993.
14. Bongarzone, I., Butti, M. G., Coronelli, S., Borrello, M. G., Santoro, M., Mondellini, P., Pilotti, S., Fusco, A., Della Porta, G., and Pierotti, M. A. Frequent activation of ret proto-oncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res., 54: 2979-2985, 1994.
15. Klugbauer, S., Demidchik, E. P., Lengfelder, E., and Rabes, H. M. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res., 58: 198-203, 1998.
16. Fugazzola, L., Pierotti, M. A., Vigano', E., Pacini, F., Vorontsova, T. V., and Bongarzone, I. Molecular and biochemical analysis of Ret/ tc4, a novel oncogenic rearrangement between Ret and Ele1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene, 13: 1093-1097, 1996.
17. Asai, N., Iwashita, T., Matsuyama, M., and Takahashi, M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol., 15 (No. 3): 1613-1619, 1995.
18. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., and Di Fiore, P. P. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (Wash. DC), 267: 381-383, 1995.
19. Iwashita, T., Asai, N., Murakami, H., Matsuyama, M., and Takahashi, M. Identification of tyrosine residues that are essential for transforming activity of the RET proto-oncogene with MEN2A or MEN2B mutation. Oncogene, 12: 481-487, 1996.
20. Iwashita, T., Kato, M., Murakami, H., Asai, N., Ishiguro, Y., Ito, S., Iwata, Y., Kawai, K., Asai, M., Kurokawa, K., Kajita, H., and Takahashi, M. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene, 18: 3919-3922, 1999.
21. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
22. Dancey, J. E., and Schoenfeldt, M. Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials. Oncology (Huntingt.), 15: 748-750, 2001.
23. Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A., Gazit, A., Levitzki, A., and Santoro, M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res., 62: 1077-1082, 2002.
24. Sato, Y., and Rifkin, D. B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell. Biol., 107: 1199-1205, 1988.
25. γ. Mol. Cell. Biol., 16 (No. 5): 2151-2163, 1996.
26. Bongarzone, I., Vigano, E., Alberti, L., Mondellini, P., Uggeri, M., Pasini, B., Borrello, M. G., and Pierotti, M. A. The Glu632-Leu633 deletion in cystein rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Oncogene, 18: 4833-4838, 1999.
27. Longva, K. E., Blystad, F. D., Stang, E., Larsen, A. M., Johannessen, L. E., and Madshus, I. H. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J. Cell. Biol., 156: 843-854, 2002.
28. Patnaik, A., Chau, V., and Wills, J. W. Ubiquitin is part of the retrovirus budding machinery. Proc. Natl. Acad. Sci. USA, 97: 13069-13074, 2000.
29. Schubert, U., Ott, D. E., Chertova, E. N., Welker, R., Tessmer, U., Princiotta, M. F., Bennink, J. R., Krausslich, H. G., and Yewdell, J. W. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA, 97: 13057-13062, 2000.
30. Strack, B., Calistri, A., Accola, M. A., Palu, G., and Gottlinger, H. G. A role for ubiquitin ligase recruitment in retrovirus release. Proc. Natl. Acad. Sci. USA, 97: 13063-13068, 2000.
31. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther., 82: 231-239, 1999.
32. Fry, D. W. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des., 15: 3-16, 2000.
33. Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., Lipkowitz, S., and Yarden, Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/ li-1. Mol. Cell, 4: 1029-1040, 1999.
34. Levkowitz, G., Oved, S., Klapper, L. N., Harari, D., Lavi, S., Sela, M., and Yarden, Y. c-Cbl is a suppressor of the neu oncogene. J. Biol. Chem., 275: 35532-35539, 2000.
35. Citri, A., Alroy, I., Lavi, S., Rubin, C., Xu, W., Grammatikakis, N., Patterson, C., Neckers, L., Fry, D. W., and Yarden, Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J., 21: 2407-2417, 2002.